Our strategy and business model
Focus on unmet medical needs resulting from specific genetic mutations, drug resistance, or compensatory mechanisms
Build a portfolio of internally discovered and selectively acquired programs structured into asset-based subsidiaries
Fast track promising assets from discovery to clinical proof of concept
Advance programs into pivotal studies and commercialization through creative partnerships
Leverage proven and synergistic capabilities of Jubilant Pharmova's world-class research with in-house development expertise
Key differentiators
Speed & Efficiency
Agile business model with asset-based subsidiaries geared for speed, efficiency and creative partnerships to rapidly bring new cures to market
Leadership
Leadership of experienced drug hunters to direct 50+ dedicated, highly skilled scientists from Jubilant Pharmova
World-class R&D Engine
Advanced R&D engine to discover and develop innovative, precision therapeutics
First-in-Class Programs and Strong IP Portfolio Including:
The only known dual epigenetic inhibitor of LSD1/HDAC6 for genetically-defined cancers First-in-class PAD4 inhibitor with potential in multiple auto-immune disorders